Vanessa Vankerckhoven | CEO & Founder
IDEVAX

Vanessa Vankerckhoven is Founder and CEO of Idevax, Belgian medical device company. She holds a PhD in Medical Sciences from the University of Antwerp, Belgium. She’s a passionate entrepreneur and also holds a position as Guest Professor at the Faculty of Medicine & Health Sciences at the University of Antwerp. She has a profound interest in vaccinology, medical microbiology, infectious diseases, oncology and medical devices. Prior to founding Idevax, she founded Novosanis in 2013 as a spin-off from the University of Antwerp, Belgium. Novosanis is medical device company active in urine sample collection and preservation. She successfully led the company through the acquisition by Orasure Technologies Inc in Jan 2019 and remained CEO until October 2022. She started her career as Research & Innovation Manager at the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium.

Appearances:

Day 1 - Tuesday 14th October @ 12:40

Start-Up Pitches

12:40 - 'Innovative Viral/RNA Platform for Infectious Diseases and Oncology'Dr Benjamin Damien , CEO, Sagitta Biotech

12:45 - 'Comprehensive Immunopeptidomics Platform for Vaccine Development and Construct Validation'Dr Elise Pepermans, CEO, ImmuneSpec

12:50 - 'Resolving challenges in preventive and therapeutic vaccination through reliable skin drug delivery devices'Dr Vanessa Vankerckhoven, CEO, Idevax

12:55 - 'eFIT: A novel electron beam platform for Vaccine Manufacturing'Daniel Becker, Head of Business Development, KyooBe Tech

13:00 - 'SafeR® Syringes — Engineering Safety and Sustainability'Bruno Vandelanotte, Head of EMEA Sales, Roncadelle Operations

13:05 - 'Unlocking Scalable Biomanufacturing for Advanced Therapies'Dirk Hahneiser, General Manager, Cocoon Bioscience

13:10 - 'Proprietary WISIT platform delivers best-in-class Parkinson vaccine'Markus Mandler, CEO & Founder, Tridem Bioscience

13:15 - Start-Up Pitch Feedback Panel

Benjamin DAMIEN, CEO, Sagitta Biotech